Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 10,713

Document Document Title
WO/2009/087981A1
Disclosed is a polymerizable compound which can be obtained by a simpler process. The polymerizable compound is represented by formula (1) or (2). [Rf-{R1-X0-(CO)t-R2-}q]mX1-R3-Z (1) Rf-R1-X2-CO(NH)r-R3-Z (2) In the formulae, Rf represen...  
WO/2009/081789A1
A compound that is useful as an agent in the prevention and treatment of circulatory system, nervous system, metabolic, reproductive system, and gastrointestinal diseases. Formula (I) is a compound represented by the following: [structur...  
WO/2009/078268A1
Disclosed is a gelling agent containing a fluoroalkyl derivative, a small amount of which can gelatinize or solidify various organic solvents. Specifically disclosed is a gelling agent for organic liquids, which contains a fluoroalkyl de...  
WO/2009/073592A3
The present invention provides fluoroalkyl amines represented by the formula R1-Q-S(O)x-C(H),(CH3)r(CH2)z+(1-1)-NHR and fluoroalkyl isocyanates and isothiocyanates represented by the formula RrQ-S(O)x-C(H)l(CH3)r(CH2)Z+(1-1)-N=C=X1, wher...  
WO/2009/072002A3
The present invention generally relates to anticancer agents and methods of treating cancer. The anticancer agents described herein comprise a bisphenol core and generally act as topoisomerase II inhibitors, though their anticancer activ...  
WO/2009/073592A2
The present invention provides fluoroalkyl amines represented by the formula R1-Q-S(O)x-C(H),(CH3)r(CH2)z+(1-1)-NHR and fluoroalkyl isocyanates and isothiocyanates represented by the formula RrQ-S(O)x-C(H)l(CH3)r(CH2)Z+(1-1)-N=C=X1, wher...  
WO/2009/070873A1
Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this recep...  
WO/2009/066952A1
Provided are a monomer for a proton-conducting polymer having an acid group in aside chain thereof, a proton-conducting polymer prepared using the monomer, a method of preparing the proton-conducting polymer, an electrolyte membrane comp...  
WO/2009/063427A1
Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R1, R2, R3 are each independently H or a C1-4 alkyl group or a C2-4 acyl group; R4 and R5 are each independently H or a group of formula -SO3R6, whe...  
WO/2009/061744A2
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (K...  
WO/2009/061744A3
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (K...  
WO/2009/049961A2
The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.  
WO/2009/049845A2
Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing...  
WO/2009/049961A3
The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.  
WO/2009/049845A3
Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing...  
WO/2009/045488A3
The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the inven...  
WO/2009/045488A2
The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the inven...  
WO/2009/043784A1
Compounds of the formula (I) wherein Ar1, Ar2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.  
WO/2009/040590A1
For the manufacturing of a complex product with advanced assimilation efficacy, including methyl-methionine sulphonium, carboxyl-uracil, paraaminobenzoic acid, dimethyl-sulfoxide and poliethoxy castor oil, and its utilization.  
WO/2009/038463A1
The invention relates to new, highly efficient UV - absorbing compounds, a process for their manufacturing and to uses of these UV - absorbing compounds. The UV - absorbing compounds are in particular UV - A - absorbing compounds accordi...  
WO/2009/030752A1
The present invention relates to compounds of formula (I) : as well as to cosmetic and pharmaceutical compositions containing such a compound.  
WO/2009/027004A1
The invention relates to a novel thermodynamically stable crystal modification of 2-({2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)me thyl]phenyl}carbonyl)cyclohexane-1,3-dione. A thermodynamically stable crystal modification of...  
WO/2009/024863A3
Disclosed herein is a convenient, commercially viable and environmentally friendly process for the preparation of Armodafinil. The present invention also provides an improved, commercially viable and industrially advantageous process for...  
WO/2009/025791A2
The invention encompasses processes for obtaining pure armodafinil substantially free of disulfide impurities that is suitable for use on an industrial scale. In particular, a processes for purifying armodafinil from bis(diphenylmethyl)d...  
WO/2009/024863A2
Disclosed herein is a convenient, commercially viable and environmentally friendly process for the preparation of Armodafinil. The present invention also provides an improved, commercially viable and industrially advantageous process for...  
WO/2009/025791A3
The invention encompasses processes for obtaining pure armodafinil substantially free of disulfide impurities that is suitable for use on an industrial scale. In particular, a processes for purifying armodafinil from bis(diphenylmethyl)d...  
WO/2009/022681A1
Disclosed is a positive resist composition which is good in pattern shape, line-edge roughness, pattern collapse, sensitivity and resolution in conventional exposure (dry exposure), liquid immersion exposure and double exposure. Also dis...  
WO/2009/018824A1
A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep disorder. The composition should be given in such an amount that it causes a less than 40 % decrease in t...  
WO/2009/014268A1
There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein G represents an oxygen atom or a sulfur atom; R2 represents a C1-C4 chain hyd...  
WO/2009/010156A2
The invention relates to compounds of formula (I) or the salts thereof, wherein Q is a (hetero)aromatic radical having up to 6 ring atoms, the ring of the heteroaromatic radical comprising 1, 2, 3 or 4 nitrogen atoms or 1 sulphur atom or...  
WO/2009/010156A3
The invention relates to compounds of formula (I) or the salts thereof, wherein Q is a (hetero)aromatic radical having up to 6 ring atoms, the ring of the heteroaromatic radical comprising 1, 2, 3 or 4 nitrogen atoms or 1 sulphur atom or...  
WO/2009/009041A3
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.  
WO/2009/008905A1
Compounds having the formula : (I) wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of phenoxy-acetic acids and analogs capable of inhibiting the lethal effects of infection by anthrax b...  
WO/2009/008905A4
Compounds having the formula : (I) wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of phenoxy-acetic acids and analogs capable of inhibiting the lethal effects of infection by anthrax b...  
WO/2009/009041A2
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.  
WO/2009/005110A3
There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally subst...  
WO/2009/005110A2
There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally subst...  
WO2008115999A8
This invention is directed to compounds of formula (I), wherein A, B, m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodr...  
WO/2008/157216A1
The present invention provides a process for the manufacture of an arylmethyl-sulfonylarene, R1CH2SO2R2, wherein R1 and R2 are each independently an optionally substituted phenyl or naphthyl group which process comprises reacting an aryl...  
WO/2008/153159A1
It is intended to provide a novel amine compound represented by the following general formula (I), a pharmaceutically acceptable acid addition salt thereof, a hydrate thereof or a solvate thereof, which has an excellent peripheral blood ...  
WO/2008/151211A1
The present invention relates to A compound of the formula Ia wherein in any of its stereoisomers forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as desc...  
WO/2008/148468A1
The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compou...  
WO/2008/149141A3
The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(-)-2-benzhydrylsulfinylacetamide and S-(+)-2- benzhydrylsulfinylacetamide respectively.  
WO/2008/149141A2
The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(-)-2-benzhydrylsulfinylacetamide and S-(+)-2- benzhydrylsulfinylacetamide respectively.  
WO/2008/143338A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C3-C10 alkenyl group optionally substituted with at least one halogen atom...  
WO/2008/143333A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods which is represented by formula (I): wherein R1 represents a C3-C6 haloalkyl group having at least one fluorine atom and at least o...  
WO/2008/143332A1
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C1-C5 haloalkyl group having at least one fluorine atom, R2 represents a C...  
WO/2008/133112A1
Disclosed is (1) a sulfone compound having a propargyl group. Also disclosed is (2) a nonaqueous electrolyte solution for lithium secondary batteries, which is obtained by dissolving an electrolyte in a nonaqueous solvent, which nonaqueo...  
WO/2008/123207A1
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...  
WO/2008/121877A3
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administerin...  

Matches 451 - 500 out of 10,713